. 2023 Oct 9;10(12):2297–2304. doi: 10.1002/acn3.51915

Table 2.

Change in ALSFRS‐R total score progression rate from baseline through 24 weeks: CENTAUR trial population versus PRO‐ACT external control group.

	Originally randomized treatment group in CENTAUR ¹		PRO‐ACT external control group (n = 85)
	PB and TURSO (n = 87) ^a	Placebo (n = 48)	PRO‐ACT external control group (n = 85)
Mean (SE) ALSFRS‐R progression rate, points/month	−1.24 (0.120)	−1.66 (0.159)	−1.66 (0.137)

ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised; ITT, intent‐to‐treat; PB and TURSO, sodium phenylbutyrate and taurursodiol; PRO‐ACT, Pooled Resource Open‐Access ALS Clinical Trials; SE, standard error.

^{^a}

Modified ITT population, which excluded two participants who died soon after randomization.